newcastl
diseas
nd
first
recogn
nineti
year
ago
continu
problem
poultri
produc
least
four
defin
panzoot
recogn
miller
koch
neg
impact
econom
livelihood
also
human
welfar
decreas
food
suppli
alder
initi
almost
simultan
identif
newcastl
diseas
indonesia
england
possibl
korea
nd
identifi
philippin
india
japan
australia
kenya
also
report
palestin
syria
french
congo
present
day
gabon
republ
congo
central
african
republ
island
sicili
europ
unit
state
part
panzoot
nd
report
hawaii
canada
mexico
central
south
america
china
throughout
europ
panzoot
aid
trade
movement
exot
psittacin
bird
without
strict
quarantin
guidelin
ubiquit
synanthrop
natur
pigeon
industri
poultri
industri
alexand
newcastl
diseas
virus
singl
strand
nonseg
neg
sens
rna
virus
encod
least
six
structur
protein
compris
one
three
genom
size
nucleotid
miller
koch
six
protein
nucleocapsid
phosphoprotein
matrix
fusion
hemagglutininneuraminidas
polymeras
sinc
nucleotid
sequenc
fusion
f
hemagglutininneuraminidas
hn
gene
newcastl
diseas
virus
ndv
publish
fusion
f
hemagglutininneuraminidas
hn
full
gene
sequenc
place
genbank
august
sequenc
motif
f
protein
cleavag
site
proven
reliabl
indic
virul
toyoda
et
al
help
develop
effici
molecular
diagnost
assay
rue
et
al
clinic
diseas
affect
neurolog
gastrointestin
reproduct
respiratori
system
miller
koch
often
observ
unvaccin
poorli
vaccin
bird
clinic
sign
vari
depend
speci
bird
strain
challeng
dose
viru
immun
host
miller
koch
viru
isol
either
specif
pathogen
free
spf
ndv
antibodyfre
embryon
chicken
egg
cell
cultur
coupl
hemagglutin
inhibit
hi
ndv
specif
antiserum
remain
definit
diagnost
assay
nd
oie
mean
death
time
minimum
lethal
dose
mdtmld
assay
perform
spf
embryon
chicken
egg
continu
provid
inform
virul
experiment
purpos
miller
koch
intracerebr
pathogen
index
icpi
requir
world
organis
anim
health
oie
due
assay
abil
discern
mix
infect
may
otherwis
miss
use
molecular
techniqu
oie
like
rna
virus
ndv
constantli
evolv
newcastl
diseas
virus
group
genet
two
class
one
genotyp
class
genotyp
class
ii
histor
group
ndv
strain
genotyp
base
similar
genom
began
way
provid
epidemiolog
inform
lomniczi
et
al
abil
explor
viru
repositori
laboratori
collect
ndv
strain
year
use
new
sequenc
technolog
provid
previous
unknown
inform
variou
strain
differ
outbreak
relat
one
anoth
better
understand
epidemiolog
relat
among
circul
ndv
genet
divers
characterist
global
distribut
crucial
develop
new
vaccin
vaccin
strategi
genet
evalu
oldest
ndv
strain
group
known
genotyp
ii
iii
iv
ix
dimitrov
et
al
genotyp
includ
predominantli
ndv
low
virul
genotyp
ii
strain
may
virul
low
virul
character
strain
iii
iv
ix
contain
cleavag
site
motif
virul
strain
exclud
one
viru
genotyp
ix
ndv
strain
isol
china
dimitrov
et
al
genotyp
v
vi
viii
regularli
isol
prior
dimitrov
et
al
genotyp
vii
first
isol
earli
itali
spain
netherland
belgium
germani
strain
genet
similar
ndv
strain
indonesia
late
lomniczi
et
al
newli
classifi
genotyp
x
strain
consist
strain
low
virul
identifi
earli
usa
diel
et
al
along
f
hn
sequenc
addit
ndv
complet
genom
sequenc
genbank
assist
phylogenet
character
addit
virul
genotyp
dimitrov
et
al
virus
genotyp
xi
exclus
isol
chicken
madagascar
seem
common
ancestri
virus
genotyp
iv
virus
genotyp
xiv
xvii
xviii
appear
limit
geograph
distribut
isol
predominantli
domest
gallinac
bird
west
central
africa
dimitrov
et
al
samuel
et
al
genotyp
xii
first
report
peru
china
also
found
colombia
dr
claudio
afonso
unpublish
data
recent
year
number
report
virus
increas
dimitrov
et
al
averag
countri
report
nd
outbreak
yearli
increas
number
genotyp
demonstr
broaden
virul
ndv
genet
divers
suggest
perhap
vaccin
may
contribut
effect
furthermor
current
use
vaccin
strain
mainli
genotyp
ii
three
seven
decad
old
genet
distant
nucleotid
distanc
current
circul
virul
ndv
dimitrov
et
al
high
genet
distanc
vaccin
contemporari
ndv
strain
prevent
effect
reduct
shed
virul
viru
vaccin
bird
discuss
later
review
miller
et
al
miller
et
al
complement
vaccin
control
nd
facilit
strict
biosecur
prevent
viru
contact
poultri
miller
koch
includ
implement
quarantin
station
import
bird
control
movement
bird
egg
insid
area
concern
stringent
proper
administr
vaccin
current
effect
contain
nd
outbreak
normal
achiev
util
combin
vaccin
rapid
diagnost
assay
cull
infect
flock
earli
late
live
inactiv
nd
vaccin
vaccin
platform
avail
use
decreas
econom
loss
result
morbid
mortal
gallili
bennathan
inactiv
vaccin
becam
commerci
avail
usa
adopt
poultri
industri
time
compar
expens
unabl
prevent
clinic
diseas
suffici
level
merit
wide
spread
use
first
live
vaccin
licens
formul
strain
design
virul
produc
diseas
younger
bird
applic
use
chicken
least
fourweek
old
need
appli
wingweb
applic
goldhaft
time
sever
laboratori
investig
ndv
strain
could
use
live
vaccin
accept
level
postvaccin
clinic
diseas
symptom
within
two
year
two
ndv
strain
low
virul
lasota
isol
chicken
usa
also
licens
use
goldhaft
hitchner
shortli
product
avail
individu
bird
administr
mass
applic
techniqu
deem
necessari
larger
commerci
set
investig
implement
despit
vari
respons
uneven
coverag
flock
less
optim
percentag
seroconvert
bird
lancast
sinc
earliest
implement
live
nd
vaccin
transfer
antibodi
offspr
even
partial
neutral
live
nd
vaccin
known
complic
also
evid
even
vaccin
formul
virul
vaccin
strain
would
provid
lifelong
immun
addit
vaccin
would
necessari
layer
breeder
unfortun
mani
problem
control
nd
clear
first
decad
nd
vaccin
use
continu
outbreak
nd
occur
infect
poultri
virul
form
viru
refer
mesogen
velogen
ndv
countri
oblig
report
oie
trade
partner
may
suspend
import
poultri
poultri
product
countri
world
livestock
diseas
atla
survey
countri
includ
oie
anim
health
yearbook
conclud
newcastl
diseas
fourth
problemat
diseas
poultri
behind
highli
pathogen
avian
influenza
avian
infecti
bronchiti
low
pathogen
influenza
anonym
evalu
number
wild
anim
lost
destruct
diseas
slaughter
nd
rank
diseas
evalu
anonym
widespread
distribut
nd
high
number
annual
outbreak
demonstr
although
global
use
current
nd
vaccin
vaccin
practic
alon
control
diseas
countri
affect
descend
order
iran
south
africa
israel
china
vietnam
columbia
romania
south
korea
kuwait
sweden
anonym
countri
report
nd
outbreak
averag
per
year
nd
rank
behind
rabi
report
diseas
outbreak
anonym
countri
confirm
nd
outbreak
domest
poultri
countri
report
nd
outbreak
respect
diseaseinformationstatuslist
underreport
nd
especi
area
virul
ndv
endem
poultri
may
mean
number
underestim
alreadi
bad
situat
mani
countri
affect
nd
also
lack
good
biosecur
practic
thu
nd
like
persist
area
world
vaccin
biosecur
practic
improv
vaccin
effort
nd
focus
poultri
sector
howev
like
bird
speci
suscept
infect
ndv
strain
date
avian
speci
document
ndv
infect
kaleta
baldauf
besid
chicken
bird
pigeon
cormor
psittacin
pheasant
peafowl
wild
waterfowl
shorebird
often
report
infect
virul
ndv
cardena
diel
et
al
pearson
mccann
ndv
low
virul
kim
et
al
gener
turkey
slightli
resist
ndv
chicken
howev
wildbird
ndv
strain
adapt
turkey
abl
infect
speci
readili
dr
patti
miller
unpublish
data
gees
duck
also
show
resist
infect
duck
rare
present
sign
clinic
diseas
gees
show
slightli
higher
suscept
depend
strain
ndv
genotyp
v
ndv
strain
began
isol
usa
addit
chicken
peafowl
among
bird
note
present
clinic
diseas
pearson
mccann
virul
ndv
strain
captiv
nonpoultri
speci
peafowl
pigeon
pheasant
parakeet
pakistan
nearli
ident
isol
chicken
geograph
locat
suggest
exist
epidemiolog
link
two
group
bird
submit
public
role
differ
bird
speci
report
infect
ndv
mainten
diseas
still
unclear
nevertheless
import
underestim
sometim
rear
larg
flock
close
proxim
poultri
vaccin
appropri
feasibl
could
contribut
control
nd
vaccin
protocol
speci
depend
nation
intern
regul
specif
epidemiolog
situat
oie
small
size
ndv
genom
along
low
likelihood
genet
recombin
facilit
use
ndv
vaccin
vector
inform
found
review
summar
bodi
knowledg
gene
individu
facilit
genet
manipul
further
recombin
ndv
rndv
vaccin
develop
ganar
et
al
viru
also
replic
mani
mammalian
speci
allow
ndv
use
vector
develop
veterinari
human
vaccin
diseas
rabi
west
nile
diseas
infecti
bursal
diseas
canin
distemp
influenza
ebola
sever
acut
respiratori
syndrom
human
immunodefici
syndrom
respiratori
syncyti
viru
syndrom
among
other
kim
samal
howev
evid
mammal
serv
biolog
vector
spread
nd
poultri
although
mammal
includ
human
often
serv
mechan
vector
viru
three
main
goal
use
vaccin
help
control
nd
decreas
elimin
clinic
diseas
ii
decreas
amount
virul
viru
shed
iii
increas
infecti
dose
challeng
viru
unfortun
first
goal
consid
object
current
control
strategi
field
veterinarian
tool
assess
effect
vaccin
accomplish
second
third
object
biosecur
critic
compon
keep
challeng
viru
away
flock
achiev
protect
level
immun
ideal
prevent
exposur
success
nd
vaccin
program
also
may
depend
minimum
flock
receiv
proper
dose
respond
vaccin
achiev
herd
immun
van
boven
et
al
studi
perform
optim
condit
remain
valid
field
suboptim
condit
may
includ
defici
nutrit
stress
immun
suppress
repeat
challeng
exemplari
current
vaccin
strategi
differ
poultri
sector
provid
merck
veterinari
manual
wwwmerckvetmanu
com
howev
vari
depend
specif
nd
epidemiolog
situat
tabl
summar
main
properti
live
inactiv
vector
vaccin
wide
use
nd
vaccin
worldwid
commonli
use
nd
vaccin
live
vaccin
virus
formul
strain
isol
virus
circul
poultri
sourc
lasota
vgga
vaccin
virus
belong
genotyp
ii
genet
antigen
highli
relat
among
nucleotid
ident
main
differ
among
vaccin
tropism
capac
replic
chicken
highest
lasota
result
higher
level
neutral
antibodi
compar
strain
meuleman
thu
lasota
strain
nearli
alway
use
countri
virul
ndv
endem
diel
et
al
vgga
strain
normal
sold
enterotrop
vaccin
strain
attenu
vaccin
use
case
low
challeng
young
bird
live
vaccin
provid
mucos
humor
immun
administ
use
mass
applic
techniqu
may
caus
clinic
respiratori
diseas
drop
egg
product
easili
inactiv
kept
requir
temperatur
commonli
c
winterfield
dhillon
effect
live
nd
vaccin
directli
correl
dose
administ
vaccin
experiment
condit
mean
embryo
infecti
vaccin
dose
eid
reliabl
achiev
protect
mortal
adult
spf
chicken
prevent
challeng
viru
infect
replic
cardena
garcia
et
al
cornax
et
al
dose
lasota
vaccin
eid
higher
produc
strong
humor
immun
respons
increas
titer
observ
challeng
suggest
littl
replic
challeng
viru
cornax
et
al
similar
surviv
rate
viral
shed
amount
challeng
virul
ndv
strain
genotyp
vii
observ
lasota
vaccin
spf
chicken
dr
cardena
garcia
univers
georgia
usa
person
commun
samuel
et
al
cornax
et
al
result
suggest
may
possibl
achiev
three
object
vaccin
high
dose
vaccin
use
cornax
et
al
result
appear
confirm
result
field
aggress
vaccin
strategi
often
result
improv
nd
control
unfortun
administr
high
dose
classic
nd
vaccin
significantli
increas
cost
vaccin
thu
practic
wide
util
second
group
tradit
vaccin
wide
use
vaccin
strain
class
ii
genotyp
ie
avirul
safe
use
chicken
age
cardena
strain
ndv
increas
stabil
heat
especi
advantag
rural
area
world
limit
refriger
strain
improv
thermost
comparison
nd
vaccin
strain
deriv
mainli
use
area
higher
ambient
temperatur
alder
seed
strain
produc
australian
centr
intern
agricultur
research
provid
countri
product
nd
vaccin
villag
poultri
flock
copland
alder
progress
identifi
character
thermost
immunogen
ndv
strain
continu
jeong
et
al
vaccin
also
effect
prevent
clinic
sign
upon
infect
virul
ndv
like
other
prevent
viral
replic
susta
et
al
addit
consider
villag
poultri
number
dose
abl
purchas
eas
vaccin
reconstitut
use
freezedri
pellet
lasota
ndv
strain
research
abl
provid
consum
friendli
costeffect
vaccin
smaller
flock
dose
heat
resist
usual
lyophil
product
lal
et
al
similar
pellet
commerci
product
formul
vgga
strain
effervesc
tablet
reconstitut
drink
water
administ
within
two
hour
mass
applic
method
inactiv
nd
vaccin
disadvantag
requir
withdraw
period
vaccin
bird
process
human
consumpt
vaccin
requir
individu
administr
subcutan
intramuscular
inject
even
though
bird
vaccin
inactiv
vaccin
tend
higher
humor
antibodi
level
develop
strong
cell
mediat
respons
schijn
et
al
shed
larger
amount
virul
challeng
viru
compar
bird
vaccin
live
nd
vaccin
miller
et
al
although
live
inactiv
vaccin
protect
clinic
diseas
spf
chicken
continu
report
vaccin
failur
field
condit
perozo
et
al
rehmani
et
al
one
possibl
reason
failur
may
poor
vaccin
respons
also
depend
fieldassoci
factor
unrel
vaccin
immunosuppress
meuleman
infect
prior
nd
vaccin
differ
avian
pathogen
infecti
bronchiti
viru
gallid
alphaherpesviru
infecti
bursal
diseas
viru
mycoplasma
spp
associ
immunosuppress
effect
understand
role
field
factor
field
immunosuppress
agent
nd
vaccin
may
lead
develop
effect
vaccin
vaccin
strategi
vaccin
coexpress
antigen
differ
pathogen
simultan
induc
immun
sever
avian
diseas
would
great
valu
presenc
matern
antibodi
interfer
develop
activ
immun
live
vaccin
administ
via
intramuscular
subcutan
intranas
rout
drink
water
aerosol
chicken
matern
immun
best
respons
live
nd
vaccin
achiev
conjunctiv
intranas
rout
administr
perhap
due
develop
local
immun
induc
vaccin
howev
immun
induc
inactiv
vaccin
less
affect
presenc
matern
antibodi
lancast
year
effort
direct
toward
develop
recombin
vaccin
nd
use
avian
virus
vector
fowlpox
viru
fpv
vectorbas
vaccin
express
ndv
f
hn
protein
proven
protect
chicken
challeng
virul
ndv
boursnel
et
al
later
multipl
studi
conduct
employ
gene
alon
combin
also
viral
gene
investig
protect
efficaci
recombin
vaccin
karaca
et
al
taylor
et
al
shown
matern
antibodi
influenza
viru
hemagglutinin
ha
protein
interfer
recombin
fpv
rfpv
vaccin
express
ha
faulkner
et
al
other
shown
immun
fpv
previou
fpv
vaccin
matern
antibodi
problem
bublot
et
al
least
two
commerci
rfpvnd
vaccin
regist
sold
commerci
howev
rfpvnd
vaccin
wide
use
appli
mass
method
furthermor
previou
exposur
fpv
commonli
present
environ
decreas
efficaci
rfpv
vaccin
meleagrid
alphaherpesviru
commonli
known
herpesviru
turkey
hvt
serotyp
marek
diseas
viru
one
wide
use
vector
recombin
vaccin
product
earli
morgan
et
al
reynold
et
al
first
show
protect
efficaci
hvt
vectorbas
vaccin
protect
chicken
nd
marek
diseas
morgan
et
al
reynold
et
al
vaccin
made
insert
code
region
fusion
protein
ndv
thymidin
kinas
site
viral
genom
capabl
express
protein
encod
gene
replic
current
two
bival
commerci
recombin
hvt
rhvt
vaccin
regist
use
intern
replic
rhvtnd
vaccin
appear
mildli
hinder
presenc
matern
antibodi
le
gro
et
al
abl
prevent
clinic
diseas
mortal
challeng
virul
ndv
six
week
vaccin
sonoda
et
al
antibodi
induc
administr
rhvtnd
vaccin
occur
time
matern
antibodi
wane
rhvtnd
vaccin
mani
benefit
among
administ
ovo
hatcheri
subcutan
hatch
produc
longterm
immun
armour
esaki
et
al
howev
rhvtnd
vaccin
cell
associ
like
marek
diseas
vaccin
requir
kept
liquid
nitrogen
administ
within
hour
thaw
unfortun
rhvtnd
requir
four
week
full
immun
reach
palya
et
al
would
requir
strictest
level
biosecur
prevent
infect
period
may
imposs
countri
nd
endem
recombin
hvt
vaccin
wide
use
countri
minimum
viral
challeng
exist
howev
endem
countri
vaccin
may
need
use
combin
nd
vaccin
confer
accept
protect
hatch
administr
kill
live
nd
vaccin
bird
vaccin
ovo
rhvtnd
vaccin
increas
level
immun
facilit
complet
protect
help
decreas
amount
virul
ndv
shed
challeng
palya
et
al
approach
commonli
refer
primeboost
strategi
lack
simpl
serolog
test
measur
immun
respons
rhvtnd
vaccin
express
ndv
fusion
protein
quantit
realtim
polymeras
chain
reaction
assay
evalu
rhvtnd
vaccin
load
feather
follicl
develop
rauw
et
al
approach
may
help
evalu
rhvt
vaccin
administr
success
commerci
elisa
kit
recent
advertis
detect
antindv
antibodi
induc
rhvtnd
vaccin
import
note
use
one
rhvt
vaccin
ovo
prevent
use
rhvtvector
vaccin
subcutan
bird
hatch
immun
induc
first
vaccin
neutral
virus
second
applic
administ
schat
howev
simultan
subcutan
administr
recombin
marek
diseas
viru
vaccin
serotyp
rispen
strain
express
protein
encod
gene
ibdv
rhvtnd
vaccin
result
surviv
challeng
five
week
vaccin
marek
diseas
viru
ibdv
ndv
respect
ishihara
et
al
recombin
infecti
bursal
diseas
viru
ibdv
contain
hn
ndv
also
creat
provid
protect
spf
bird
follow
virul
ndv
challeng
li
et
al
late
revers
genet
technolog
develop
rescu
infecti
ndv
assembl
subgenom
overlap
cdna
fragment
control
rna
polymeras
promot
peeter
et
al
romeroberdorf
et
al
technolog
allow
research
genet
manipul
genom
ndv
insert
nonndv
gene
lead
develop
genet
engin
vaccin
retain
replic
compet
origin
viru
sinc
use
revers
genet
technolog
mani
strain
ndv
develop
vector
express
protein
encod
insert
foreign
gene
purpos
develop
avian
vaccin
human
cancer
therapi
comprehens
review
list
main
featur
ndv
allow
promis
vaccin
vector
replic
well
vivo
induc
robust
mucos
system
immun
respons
allow
easi
genet
manipul
avirul
strain
usual
use
vaccin
vector
safe
recombin
incorpor
dna
genom
replic
kim
samal
mani
recombin
nd
vaccin
creat
insert
foreign
gene
intergen
region
ndv
genom
express
dual
use
vaccin
ndv
second
agent
evalu
vaccin
candid
clinic
trial
reveal
differ
level
protect
target
pathogen
challeng
dinapoli
et
al
huang
et
al
nakaya
et
al
park
et
al
yu
et
al
although
yet
commerci
avail
numer
experiment
vaccin
use
ndv
low
virul
vector
develop
investig
protect
differ
avian
diseas
huang
et
al
report
gener
lasota
vectorbas
vaccin
express
protein
variant
ibdv
huang
et
al
decad
later
anoth
experiment
recombin
ndv
rndv
ibdv
vaccin
evalu
spf
commerci
broiler
ovo
administr
result
hatchabl
surviv
intramuscular
challeng
virul
ndv
ge
et
al
two
team
report
success
formul
ndv
lasota
vectorbas
vaccin
express
gallid
alphaherpesviru
commonli
known
infecti
laryngotrach
viru
surfac
glycoprotein
gb
gc
gd
togeth
separ
kanabagatt
basavarajappa
et
al
zhao
et
al
primeboost
applic
spf
bird
surviv
virul
ndv
challeng
two
week
last
vaccin
administ
kanabagatt
basavarajappa
et
al
year
recombin
lasota
viru
contain
ibv
gene
also
gener
prime
vaccin
toro
et
al
follow
emerg
worldwid
spread
high
pathogen
avian
influenza
viru
hpaiv
increas
need
better
protect
poultri
industri
hpai
low
pathogen
avian
influenza
multipl
ndv
vectorbas
vaccin
contain
differ
avian
influenza
viru
aiv
hemagglutinin
ha
gene
creat
replac
polybas
cleavag
site
hpaiv
low
pathogen
cleavag
site
eg
goff
et
al
lardinoi
et
al
park
et
al
romeroberdorf
et
al
schroer
et
al
recent
experiment
use
modifi
virul
ndv
vectorbas
vaccin
express
aiv
protein
report
show
potenti
virul
ndv
use
vector
kim
et
al
ndv
vectorbas
vaccin
express
protein
recent
commerci
sarfatimizrahi
et
al
rndvaiv
vaccin
heavili
use
field
china
roughli
billion
dose
appli
li
et
al
limit
data
mexico
avail
threemonth
period
million
dose
rndvaiv
administ
villarr
addit
convent
model
foreign
gene
express
addit
independ
transcript
unit
itu
differ
approach
express
foreign
gene
ndv
explor
wen
et
al
gao
et
al
increas
capac
express
larger
gene
one
foreign
gene
express
foreign
protein
intern
ribosom
entri
site
ire
second
open
read
frame
ndv
vector
also
investig
result
suggest
np
gene
downstream
noncod
region
optim
insert
site
high
level
foreign
gene
protein
express
rndv
vaccin
equal
level
immunogen
abil
replic
chicken
therefor
vaccin
creat
evalu
abil
replic
chicken
induc
protect
immun
respons
virul
ndv
challeng
immun
respons
vaccin
recombin
vaccin
influenc
mani
factor
express
desir
level
foreign
gene
undoubtedli
one
import
critic
factor
success
vaccin
level
foreign
gene
express
ndv
vector
affect
rate
replic
tissu
tropism
viral
vector
size
sequenc
foreign
gene
insert
genom
locat
foreign
gene
vector
among
genom
locat
foreign
gene
shown
crucial
date
foreign
gene
insert
noncod
region
ndv
genom
addit
independ
transcript
unit
consist
ndv
gene
start
gs
foreign
gene
ndv
gene
end
ge
sequenc
dinapoli
et
al
huang
et
al
nakaya
et
al
park
et
al
yu
et
al
zhao
et
al
base
sequenti
transcript
neg
strand
rna
virus
lamb
park
best
posit
foreign
gene
express
hypothes
closest
ndv
genom
howev
insert
foreign
gene
itu
promoterproxim
posit
may
interfer
ndv
replic
serious
promoterdist
posit
result
lower
level
foreign
gene
express
carnero
et
al
zhao
peeter
zhao
et
al
therefor
balanc
viru
replic
abund
foreign
gene
express
must
consid
select
foreign
gene
insert
site
insert
foreign
gene
proxim
end
np
p
gene
express
low
level
foreign
protein
carnero
et
al
studi
support
conclus
p
junction
region
optim
insert
site
optim
level
foreign
gene
express
ndv
vector
nakaya
et
al
zhao
et
al
import
aspect
consid
use
ndv
vaccin
vector
efficaci
viru
presenc
vectorand
insertspecif
matern
antibodi
armour
previous
demonstr
efficaci
recombin
ndv
vectorbas
vaccin
express
avian
influenza
protein
reduc
vaccin
administ
bird
preexist
antind
antiaiv
antibodi
faulkner
et
al
sarfatimizrahi
et
al
schroer
et
al
notabl
rndv
vectorbas
vaccin
evalu
ndvchalleng
experi
autogen
vaccin
first
true
antigen
match
vaccin
use
poultri
smith
howev
autogen
vaccin
defin
difficult
use
especi
food
anim
usual
inactiv
long
withdraw
period
uncommon
viru
strain
use
vaccin
respiratori
diseas
caus
paramyxovirus
measl
canin
distemp
chang
time
improv
efficaci
vaccin
achiev
immun
griffin
pan
martella
et
al
chang
made
virul
challeng
strain
accumul
mani
genom
mutat
time
vaccin
viru
strain
longer
similar
antigen
challeng
strain
avian
influenza
virus
multipl
serotyp
requir
serotyp
specif
vaccin
prevent
morbid
mortal
addit
shed
virul
hpai
challeng
viru
infect
decreas
smaller
amount
hpai
shed
vaccin
challeng
viru
similar
swayn
principl
util
ndv
strain
close
relat
homolog
challeng
strain
test
laboratori
produc
similar
find
miller
et
al
miller
et
al
live
inactiv
antigen
match
nd
vaccin
develop
use
revers
genet
one
type
vaccin
contain
virus
ident
circul
virul
ndv
except
fusion
protein
cleavag
site
modifi
decreas
virul
anoth
type
vaccin
develop
laboratori
base
use
vaccin
backbon
eg
lasota
replac
fusion
hemagglutinin
neuraminidas
gene
two
gene
replac
one
homolog
current
circul
virus
modif
cleavag
site
fusion
protein
normal
engin
ident
cleavag
site
lasota
vaccin
strain
live
inactiv
nd
vaccin
strain
antigen
match
produc
higher
humor
immun
respons
challeng
virus
heterolog
vaccin
amount
virul
nd
challeng
viru
shed
vaccin
bird
lower
amount
secret
heterolog
vaccin
miller
et
al
miller
et
al
efficaci
inactiv
vaccin
genotyp
ii
v
vi
vii
xii
challeng
virus
differ
genotyp
evalu
found
optim
condit
prevent
bird
morbid
mortal
virul
ndv
strain
use
matter
genotyp
miller
et
al
miller
et
al
howev
heterolog
nonmatch
genotyp
live
inactiv
nd
vaccin
administ
properli
chicken
given
enough
time
develop
proper
immun
respons
bird
live
show
sign
diseas
support
claim
administr
proper
amount
vaccin
also
crucial
nd
control
dortman
et
al
recent
recombin
nd
vaccin
f
hn
protein
gene
homolog
challeng
viru
lasota
backbon
shown
induc
higher
level
antibodi
reduc
viral
shed
challeng
comparison
commerci
lasota
vaccin
furthermor
bird
suboptim
vaccin
low
dose
vaccin
given
seven
day
challeng
virul
ndv
decreas
morbid
mortal
rate
observ
one
homolog
vaccin
compar
tradit
heterolog
nd
vaccin
cardena
garcia
et
al
team
korea
cho
et
al
china
indonesia
xiao
et
al
similar
find
term
reduct
viral
shed
other
report
improv
homolog
rndv
vaccin
dortman
et
al
primari
benefit
antigen
match
vaccin
compar
tradit
vaccin
possibl
decreas
amount
challeng
viru
shed
vaccin
chicken
paramet
one
routin
part
evalu
nd
vaccin
efficaci
commerci
product
recent
find
improv
clinic
protect
suboptim
vaccin
chicken
suggest
advantag
antigen
match
vaccin
may
even
clearer
field
laboratori
condit
vaccin
homolog
ndv
genotyp
v
heavili
use
mexico
billion
dose
appli
januari
juli
dr
arnulfo
toscano
aplicada
sade
cv
mexico
person
commun
suggest
market
start
appreci
benefit
reduct
viral
shed
disadvantag
homolog
vaccin
difficulti
vaccin
compani
work
virul
ndv
laboratori
need
higher
biosecur
countri
vaccin
compani
level
biosecur
safe
make
antigen
match
vaccin
chicken
vaccin
conveni
ovo
day
embryon
move
hatch
tray
system
present
ndv
antigen
respiratori
gastrointestin
tract
allow
newli
hatch
chicken
develop
earli
immun
respons
kapczynski
et
al
howev
live
ndv
given
ovo
caus
decreas
hatchabl
weak
chick
innov
approach
develop
use
antigenantibodi
complex
live
nd
vaccin
ovo
vaccin
slow
replic
without
advers
affect
hatchabl
ndv
specif
antibodi
abl
dissoci
vaccin
viru
bird
hatch
result
accept
hatchabl
otherwis
achiev
even
least
virul
asymptomat
wild
type
recombin
ndv
strain
administ
ovo
kapczynski
et
al
last
decad
understand
mechan
innat
immun
increas
significantli
innat
immun
system
specif
recogn
foreign
pathogen
pathogenassoci
molecular
pattern
help
pattern
recognit
receptor
prr
tolllik
receptor
tlr
type
prr
effort
made
enhanc
vaccin
potenc
stimul
immun
respons
use
tlr
ligand
adjuv
gupta
et
al
recent
review
gupta
et
al
chicken
tlr
agonist
use
adjuv
vaccin
poultri
infecti
diseas
includ
nd
extens
describ
gupta
et
al
ramakrishnan
colleagu
demonstr
signific
upregul
transcript
express
interferon
ifn
b
ifng
interleukin
il
gene
chicken
peripher
blood
mononuclear
cell
administr
resiquimod
agonist
synerget
effect
lipopolysaccharid
agonist
use
adjuv
inactiv
nd
vaccin
administ
intramuscularli
chicken
show
significantli
upregul
express
ifna
ifnb
ifng
induc
nitric
oxid
synthas
mhcii
gene
increas
protect
virul
ndv
challeng
compar
two
inactiv
nd
vaccin
use
alon
lipopolysaccharid
use
combin
liposom
encapsul
ndv
administ
chicken
via
intranas
rout
induc
signific
tracheal
iga
serum
igg
level
increas
level
cell
surviv
virul
ndv
challeng
tseng
et
al
polyinosin
polycytidyl
acid
poli
c
ligand
use
chicken
embryo
cell
expos
ndv
induc
antivir
state
reduc
plaqueform
capac
ndv
gupta
et
al
anoth
approach
util
tlr
agonist
effect
use
oligodeoxynucleotid
contain
unmethyl
cpg
motif
cpg
odn
also
proven
immunostimulatori
effect
cpg
motif
recogn
pathogen
pattern
innat
immun
system
activ
defens
mechan
induc
immun
respons
immun
chicken
vleugel
et
al
intern
target
cell
cpg
odn
reach
late
endosomallysosom
compart
signal
interact
chicken
ortholog
intramuscular
intranas
administr
cpg
odn
enhanc
activ
nd
vaccin
chicken
increas
system
antigenspecif
igg
level
serum
tcell
prolifer
mucos
iga
level
administ
intranas
specificpathogenfre
chicken
covaccin
nd
vaccin
least
mg
cpg
odn
either
rout
protect
challeng
otherwis
lethal
dose
virul
ndv
zhang
et
al
zhang
et
al
vaccin
contain
cpg
odn
appli
either
system
via
mucosa
good
safeti
profil
increas
immunogen
coadminist
vaccin
improv
function
profession
antigenpres
cell
boost
humor
cellular
vaccinespecif
immun
respons
highlight
potenti
use
effect
adjuv
ndv
poultri
vaccin
vleugel
et
al
coexpress
immunostimulatori
cytokin
viru
vector
suggest
improv
protect
immun
induc
sever
avian
vaccin
armour
chicken
ifng
chiinfg
macrophag
activ
modul
inhibit
viral
replic
promot
develop
respons
inhibit
cytokin
product
enhanc
antigen
present
antigen
process
destruct
intracellular
pathogen
cytokin
shown
improv
protect
enhanc
immun
respons
avian
speci
differ
avian
pathogen
howev
commerci
product
ever
reach
market
controversi
result
highlight
need
evalu
potenti
cytokin
cardena
garcia
et
al
cardena
garcia
et
al
demonstr
codeliv
chicken
ifng
nd
vaccin
use
three
vaccin
system
dnavaccin
administ
ovo
recombin
vaccin
express
chiinfg
use
ovo
inactiv
recombin
vaccin
express
chiinfg
administ
subcutan
twoweekold
spf
chicken
improv
immunogen
protect
efficaci
evalu
vaccin
candid
cardena
garcia
et
al
express
chicken
highli
virul
strain
ndv
led
decreas
system
viral
load
significantli
affect
mortal
chicken
susta
et
al
express
ifng
virul
ndv
attenu
viru
decreas
morbid
mortal
spf
chicken
susta
et
al
activ
tlr
overexpress
certain
cytokin
result
upor
downregul
variou
interleukin
chemokin
interferon
turn
direct
immun
respons
toward
either
mix
immun
respons
tlr
combin
produc
stronger
select
immun
respons
other
downregul
cytokin
express
gupta
et
al
cytokin
compon
finebalanc
network
immun
respons
multipl
feedback
loop
schat
thu
possibl
insert
cytokin
gene
use
tlr
ligand
may
deregul
finetun
exist
natur
perfectlytim
system
lead
enhanc
immun
respons
cardena
garcia
et
al
addit
immunomodulatori
effect
cytokin
tlr
ligand
may
depend
variou
factor
type
pathogen
amount
type
codeliv
antigen
rel
time
administr
amount
deliv
cytokineligand
studi
evalu
approach
level
protect
induc
comparison
exist
tradit
vaccin
necessari
use
adjuv
enhanc
immun
respons
induc
nd
vaccin
also
investig
chitosan
nontox
biocompat
biodegrad
polysaccharid
deriv
exoskeleton
crustacean
insect
shown
improv
pathway
immun
induc
stronger
earlier
peripher
cellular
immun
respons
effect
system
lachrym
digest
antibodymedi
immun
oculonas
codeliveri
live
nd
vaccin
dayold
chicken
rauw
et
al
scheme
also
evalu
second
vaccin
ovo
vaccin
rhvtnd
vaccin
day
embryon
combin
rhvtnd
mucos
codeliveri
live
ndv
chitosan
demonstr
best
protect
mortal
morbid
well
strongest
reduct
viru
shed
correl
higher
level
cellular
immun
gastrointestin
antibodymedi
immun
comparison
vaccin
use
alon
rauw
et
al
rapid
develop
nanotechnolog
provid
variou
biodegrad
nanomateri
becom
use
vaccin
research
particular
nanoparticl
system
long
develop
vaccin
deliveri
vehicl
human
vaccin
provid
protect
matern
antibodi
nucleas
lead
interest
use
anim
pathogen
chahal
et
al
dai
et
al
zhao
et
al
nanoparticl
deliveri
system
protect
deliv
antigen
disrupt
advantag
higher
antigen
uptak
control
releas
increas
durat
respons
dai
et
al
zhao
et
al
mani
type
materi
polylact
acid
poli
lactidecoglycolid
calcium
phosphat
carboxymethylcellulos
chitosan
magnesium
phosphat
among
other
use
nanoparticl
carrier
administ
multipl
rout
includ
oral
mucos
parenter
dai
et
al
zhao
et
al
two
chitosan
deriv
hydroxypropyltrimethyl
ammonium
chlorid
chitosan
trimethyl
ammoniumchlorid
chitosan
util
make
nanoparticl
mucos
deliveri
vehicl
live
attenu
nd
vaccin
dai
et
al
zhao
et
al
system
releas
ndv
effect
sustain
result
stronger
cellular
humor
mucos
immun
respons
measur
level
specif
humor
local
antibodi
spleen
lymphocyt
prolifer
level
cytokin
system
also
confer
protect
upon
challeng
virul
ndv
clinic
sign
microscop
lesion
observ
vaccin
bird
mortal
hyperplast
chang
observ
chicken
vaccin
tradit
commerci
nd
vaccin
silver
sio
doubl
hydroxid
sio
nanoparticl
develop
intranas
deliveri
dna
nd
vaccin
zhao
et
al
zhao
et
al
experi
spf
chicken
sio
nanoparticl
show
low
toxic
sustain
releas
initi
burst
induc
stronger
cellular
humor
mucos
immun
respons
compar
intramuscular
administr
vaccin
nake
dna
plasmid
system
demonstr
protect
chicken
challeng
virul
ndv
strain
great
potenti
lie
nonretrovir
mrnabas
vaccin
recent
deliveri
system
requir
deploy
convent
unmodifi
replicon
mrna
base
genom
venezuelan
equin
enceph
viru
veev
vaccin
develop
chahal
et
al
system
support
selfamplif
via
doublestrand
rna
intermedi
cytoplasm
drive
effici
express
immunogen
antigen
singl
dose
modifi
dendrim
nanoparticl
mdnp
deliv
veev
replicon
rna
encod
singl
multipl
pathogen
protein
shown
protect
mice
lethal
infect
influenza
viru
ebola
viru
toxoplasma
gondii
synthet
highli
innov
adjuvantfre
system
flexibl
multiplex
coformul
coexpress
differ
antigenexpress
replicon
ie
simultan
rais
immun
multipl
antigen
singl
diseas
andor
multipl
antigen
multipl
diseas
moreov
induc
vital
antigenspecif
tcell
antibodi
respons
without
addit
adjuv
chahal
et
al
system
test
chicken
main
advantag
design
product
vaccin
take
week
requir
high
biosecur
level
facil
allow
rapid
ondemand
respons
current
circul
pathogen
includ
highli
divers
ndv
strain
viruslik
particl
vlp
although
avail
long
time
increasingli
consid
viral
vaccin
vlp
form
assembl
viral
structur
protein
lipid
without
incorpor
viral
genom
may
offer
signific
advantag
mani
current
use
develop
vaccin
technolog
infecti
spread
infect
ii
chanc
revers
virul
recombin
iii
mimic
structur
infecti
viru
iv
immunogen
v
stimul
humor
cellular
immun
respons
mcginn
et
al
morrison
mani
differ
paramyxoviru
vlp
produc
upon
express
protein
protein
variou
combin
glycoprotein
np
transfect
cell
vector
contain
cdna
encod
protein
nd
vlp
high
effici
releas
morrison
newcastl
diseas
vlp
although
commerci
potenti
incorpor
glycoprotein
differ
strain
ndv
could
potenti
use
differ
nd
virus
mcginn
et
al
signific
potenti
applic
design
express
protein
sequenc
mani
pathogen
morrison
one
aspect
vaccin
product
address
mani
area
world
qualiti
assur
standard
product
test
nd
vaccin
gallili
code
feder
registr
titl
anim
plant
health
inspect
servic
aphi
unit
state
depart
agricultur
usda
section
manual
diagnost
test
vaccin
terrestri
anim
section
principl
vaccin
product
oie
oie
oie
council
direct
commiss
european
commun
regul
develop
test
nd
vaccin
ensur
reliabl
safe
effect
product
avail
howev
recent
nd
vaccin
illeg
transport
mexico
intend
use
fight
gamecock
california
usa
confisc
border
countri
shown
contamin
virul
ndv
addit
vaccin
ndv
strain
pedersen
et
al
extens
use
current
avail
vaccin
strict
quarantin
combin
rapid
diagnost
biosecur
stamp
contain
measur
seem
keep
nd
control
develop
countri
howev
evid
multipl
outbreak
occur
worldwid
current
vaccin
strategi
fulli
efficaci
differ
environment
condit
develop
new
concept
vaccin
gener
need
enhanc
efficaci
vaccin
improv
immun
respons
induc
investig
innov
approach
togeth
develop
safe
novel
strong
adjuv
necessari
futur
nd
vaccin
system
allow
rapid
develop
target
emerg
ndv
strain
enabl
design
multiplex
vaccin
advantag
current
exist
vaccin
none
